Bausch Health Companies Inc. (BHC)
After hours:
| Previous Close | 8.60 |
| Open | 8.57 |
| Bid | 0.00 x 4000 |
| Ask | 0.00 x 800 |
| Day's Range | 8.55 - 8.76 |
| 52 Week Range | 5.57 - 11.46 |
| Volume | |
| Avg. Volume | 2,758,550 |
| Market Cap | 3.186B |
| Beta (5Y Monthly) | 0.86 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Nov 10, 2010 |
| 1y Target Est | N/A |
- ACCESSWIRE
Bausch Health to Announce First-Quarter 2024 Results on May 2
LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST ...
- ACCESSWIRE
Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. Court of Appeals for the Federal Circuit in the matter of Salix Pharmaceuticals, ...
- ACCESSWIRE
Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan
LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that its topical prescription treatment for acne vulgaris, PrARAZLOTM (tazarotene lotion, 0.045% w/w), ...
